Skip to content
Sequence Bio logo

Sequence Bio

Sequence Bio is a YC Summer 2019 (S19) company. Based in St. John's, NL, Canada. Team of 52.

  • Genomics
  • Therapeutics
  • Drug discovery

About Sequence Bio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Sequence Bio studies the genetics of multigenerational families in Newfoundland and Labrador to identify the causal drivers of inherited disease. The population's founder effect concentrates rare genetic variants, letting researchers move from statistical association to causal evidence when linking genes to specific conditions. That causal evidence is used to surface drug targets and disease predictors earlier in development, replacing the trial-and-error approach that causes most drug candidates to fail before reaching patients.

Go-to-market

Pharmaceutical and life sciences companies partner with Sequence Bio to access its genetic insights and accelerate drug target discovery, combining Sequence Bio's population data with partners' global development capabilities.

From the Y Combinator listing

How Sequence Bio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Discovering the true signals of disease to power life-changing drugs.

90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
St. John's, NL, Canada
Team size
52
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works